197 related articles for article (PubMed ID: 22249747)
1. Pharmacophore modeling, molecular docking, and molecular dynamics simulation approaches for identifying new lead compounds for inhibiting aldose reductase 2.
Sakkiah S; Thangapandian S; Lee KW
J Mol Model; 2012 Jul; 18(7):3267-82. PubMed ID: 22249747
[TBL] [Abstract][Full Text] [Related]
2. 3D QSAR pharmacophore-based virtual screening for the identification of potential inhibitors of tyrosinase.
Ghayas S; Ali Masood M; Parveen R; Aquib M; Farooq MA; Banerjee P; Sambhare S; Bavi R
J Biomol Struct Dyn; 2020 Jul; 38(10):2916-2927. PubMed ID: 31334690
[TBL] [Abstract][Full Text] [Related]
3. Pharmacophore modeling, virtual screening, molecular docking studies and density functional theory approaches to identify novel ketohexokinase (KHK) inhibitors.
Kavitha R; Karunagaran S; Chandrabose SS; Lee KW; Meganathan C
Biosystems; 2015 Dec; 138():39-52. PubMed ID: 26521124
[TBL] [Abstract][Full Text] [Related]
4. Pharmacophore-based virtual screening and density functional theory approach to identifying novel butyrylcholinesterase inhibitors.
Sakkiah S; Lee KW
Acta Pharmacol Sin; 2012 Jul; 33(7):964-78. PubMed ID: 22684028
[TBL] [Abstract][Full Text] [Related]
5. Validation of TZD Scaffold as Potential ARIs: Pharmacophore Modeling, Atom-based 3D QSAR and Docking Studies.
Dahiya L; Mahapatra MK; Kaur R; Kumar V; Kumar M
Comb Chem High Throughput Screen; 2017; 20(4):310-320. PubMed ID: 28302016
[TBL] [Abstract][Full Text] [Related]
6. Novel insights into the structural requirements for the design of selective and specific aldose reductase inhibitors.
Kumar H; Shah A; Sobhia ME
J Mol Model; 2012 May; 18(5):1791-9. PubMed ID: 21833829
[TBL] [Abstract][Full Text] [Related]
7. Induced fit docking, pharmacophore modeling, and molecular dynamic simulations on thiazolidinedione derivatives to explore key interactions with Tyr48 in polyol pathway.
Vijjulatha M; Lingala Y; Merugu RT
J Mol Model; 2014 Jul; 20(7):2348. PubMed ID: 24974084
[TBL] [Abstract][Full Text] [Related]
8. Pharmacophore modeling and virtual screening studies of checkpoint kinase 1 inhibitors.
Chen JJ; Liu TL; Yang LJ; Li LL; Wei YQ; Yang SY
Chem Pharm Bull (Tokyo); 2009 Jul; 57(7):704-9. PubMed ID: 19571415
[TBL] [Abstract][Full Text] [Related]
9. Exploration for novel inhibitors showing back-to-front approach against VEGFR-2 kinase domain (4AG8) employing molecular docking mechanism and molecular dynamics simulations.
Rampogu S; Baek A; Zeb A; Lee KW
BMC Cancer; 2018 Mar; 18(1):264. PubMed ID: 29514608
[TBL] [Abstract][Full Text] [Related]
10. A specific pharmacophore model of sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors.
Tang C; Zhu X; Huang D; Zan X; Yang B; Li Y; Du X; Qian H; Huang W
J Mol Model; 2012 Jun; 18(6):2795-804. PubMed ID: 22120948
[TBL] [Abstract][Full Text] [Related]
11. Hydrogen bonding interactions between aldose reductase complexed with NADP(H) and inhibitor tolrestat studied by molecular dynamics simulations and binding assay.
Lee YS; Hodoscek M; Kador PF; Sugiyama K
Chem Biol Interact; 2003 Feb; 143-144():307-16. PubMed ID: 12604217
[TBL] [Abstract][Full Text] [Related]
12. Exploration of Novel Inhibitors for Bruton's Tyrosine Kinase by 3D QSAR Modeling and Molecular Dynamics Simulation.
Bavi R; Kumar R; Choi L; Woo Lee K
PLoS One; 2016; 11(1):e0147190. PubMed ID: 26784025
[TBL] [Abstract][Full Text] [Related]
13. Discovery of new inhibitors of aldose reductase from molecular docking and database screening.
Rastelli G; Ferrari AM; Costantino L; Gamberini MC
Bioorg Med Chem; 2002 May; 10(5):1437-50. PubMed ID: 11886806
[TBL] [Abstract][Full Text] [Related]
14. Discover potential inhibitors for PFKFB3 using 3D-QSAR, virtual screening, molecular docking and molecular dynamics simulation.
Bao Y; Zhou L; Dai D; Zhu X; Hu Y; Qiu Y
J Recept Signal Transduct Res; 2018; 38(5-6):413-431. PubMed ID: 30822195
[TBL] [Abstract][Full Text] [Related]
15. Tubulin inhibitors: pharmacophore modeling, virtual screening and molecular docking.
Niu MM; Qin JY; Tian CP; Yan XF; Dong FG; Cheng ZQ; Fida G; Yang M; Chen HY; Gu YQ
Acta Pharmacol Sin; 2014 Jul; 35(7):967-79. PubMed ID: 24909516
[TBL] [Abstract][Full Text] [Related]
16. Search for non-acidic ALR2 inhibitors: Evaluation of flavones as targeted agents for the management of diabetic complications.
Vyas B; Choudhary S; Singh PK; Kumar M; Verma H; Singh M; Malik AK; Silakari O
Bioorg Chem; 2020 Mar; 96():103570. PubMed ID: 31978681
[TBL] [Abstract][Full Text] [Related]
17. Predicting tyrosinase inhibition by 3D QSAR pharmacophore models and designing potential tyrosinase inhibitors from Traditional Chinese medicine database.
Gao H
Phytomedicine; 2018 Jan; 38():145-157. PubMed ID: 29425647
[TBL] [Abstract][Full Text] [Related]
18. Novel virtual lead identification in the discovery of hematopoietic cell kinase (HCK) inhibitors: application of 3D QSAR and molecular dynamics simulation.
Bavi R; Kumar R; Rampogu S; Kim Y; Kwon YJ; Park SJ; Lee KW
J Recept Signal Transduct Res; 2017 Jun; 37(3):224-238. PubMed ID: 27485399
[TBL] [Abstract][Full Text] [Related]
19. Investigation of non-hydroxamate scaffolds against HDAC6 inhibition: A pharmacophore modeling, molecular docking, and molecular dynamics simulation approach.
Zeb A; Park C; Son M; Rampogu S; Alam SI; Park SJ; Lee KW
J Bioinform Comput Biol; 2018 Jun; 16(3):1840015. PubMed ID: 29945500
[TBL] [Abstract][Full Text] [Related]
20. In silico screening and study of novel ERK2 inhibitors using 3D QSAR, docking and molecular dynamics.
Larif S; Salem CB; Hmouda H; Bouraoui K
J Mol Graph Model; 2014 Sep; 53():1-12. PubMed ID: 25064438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
